A modified gene trap approach for improved high-throughput cancer drug discovery

• DOI: 10.1038/s41388-018-0274-4
• Publication Date: 2018-04-30T09:13:32Z
• Authors: Shelli M. Morris; Andrew J. Mhyre; Savanna S. Carmack; Carrie H. Myers; Connor Burns; Wenjuan Ye; Marc Ferrer; James M. Olson; Richard A. Klingh...
• Keywords: Proto-Oncogene Proteins B-raf; 0301 basic medicine; Skin Neoplasms; Pyridones; Antineoplastic Agents; Pyrimidinones; Article; Cell Line; 3. Good health; Mice; 03 medical and health sciences; HEK293 Cells; Pyrimidines; Melanoma, Cutaneous Malignant; Vemurafenib; Cell Line, Tumor; Drug Discovery; Animals; Humans; Female; Mitogen-Activated Protein Kinases; Phosphorylation; Melanoma; Protein Kinase Inhibitors

While advances in laboratory automation has dramatically increased throughout of compound screening efforts, development of robust cell-based assays in relevant disease models remain resource-intensive and time-consuming, presenting a bottleneck to drug discovery campaigns. To address this issue, we present a modified gene trap approach to efficiently generate pathway-specific reporters that result in a robust "on" signal when the pathway of interest is inhibited. In this proof-of-concept study, we used vemurafenib and trametinib to identify traps that specifically detect inhibition of the mitogen-activated protein kinase (MAPK) pathway in a model of BRAFV600E driven human malignant melanoma. We demonstrate that insertion of our trap into particular loci results in remarkably specific detection of MAPK pathway inhibitors over compounds targeting any other pathway or cellular function. The accuracy of our approach was highlighted in a pilot screen of ~6000 compounds where 40 actives were detected, including 18 MEK, 10 RAF, and 3 ERK inhibitors along with a few compounds representing previously under-characterized inhibitors of the MAPK pathway. One such compound, bafetinib, a second generation BCR/ABL inhibitor, reduced phosphorylation of ERK and when combined with trametinib, both in vitro and in vivo, reduced growth of vemurafenib resistant melanoma cells. While piloted in a model of BRAF-driven melanoma, our results set the stage for using this approach to rapidly generate reporters against any transcriptionally active pathway across a wide variety of disease-relevant cell-based models to expedite drug discovery efforts.